Epilepsy with myoclonic atonic seizures: what to do when later-line antiseizure medications have not achieved seizure control
This protocol covers the management of epilepsy with myoclonic atonic seizures at a stage where multiple antiseizure medication trials — including agents from later treatment stages — have failed to achieve adequate seizure reduction or seizure freedom.
Previous treatment line & failure condition
The prior treatment line involved later-stage antiseizure medications, such as lamotrigine combined with valproate and a benzodiazepine, add-on cannabidiol, sulthiame, felbamate, topiramate, zonisamide, or perampanel. The intended goals were at least a 50% reduction in seizure frequency, or ideally full seizure freedom. Failure to reach either target triggers escalation to this next-line protocol.
Next-line approach
At this stage, an invasive treatment approach enters consideration — one that is explicitly reserved for situations where a substantial number of prior therapies, including dietary interventions, have been exhausted. The complete structured protocol — including specific intervention criteria and the evidence behind it — is available below.
References
Invasive treatment such as vagus nerve stimulation or corpus callosotomy are strongly discouraged early in the disease course unless four or five treatments, including the ketogenic diet, have failed.
View source ↗